At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNA Avidity Biosciences, Inc.
Trading 10-24 10:20:49 EDT
45.95
+0.55
+1.21%
High46.29
Low45.32
Vol51.63K
Open45.47
D1 Closing45.40
Amplitude2.13%
Mkt Cap5.38B
Tradable Cap4.45B
Total Shares117.12M
T/O2.37M
T/O Rate0.05%
Tradable Shares96.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
BRIEF-Wave Life Sciences Announces First-Ever Therapeutic RNA Editing In Humans Achieved In Restoraation-2 Trial Of WVE-006 In Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.